CDKN2A and endometrial cancer: CDKN2A was associated with several cancer-related pathways, including colorectal cancer, endometrial cancer, and pancreatic cancer, while HSD17B1 was enriched in metabolic and signaling pathways, such as galactose metabolism and MAPK signaling.